Advice for Clinicians Administering Bispecifics to Patients With R/R MM
Drs Costello and Pianko close their discussion by sharing advice for clinicians administering bispecifics to their patients with relapsed/refractory multiple myeloma.
Outpatient Management of Teclistamab for R/R MM
Experts discuss key data on the outpatient management of teclistamab.
Monitoring Patients With R/R MM for CRS and ICANS
Matthew Pianko, MD, explains how patients with relapsed/refractory multiple myeloma are monitored for CRS and ICANS.
Administering Teclistamab for R/R MM in an Outpatient Setting
Caitlin Costello, MD, shares her thoughts on administering teclistamab to patients with relapsed/refractory multiple myeloma in an outpatient setting.
Administering Bispecifics to Patients with R/R MM
Key opinion leaders discuss how bispecifics are administered at their institutions.
Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
HER2-Targeted Therapy in Upper GI Cancer
Sam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.
The Role for Comprehensive NGS Testing in Upper GI Cancers
Medical oncologists discuss the role for comprehensive next-generation sequencing (NGS) in upper GI cancers and the potential role for zolbetuximab.
Treatment Paradigm for Metastatic Upper GI Cancers
Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.
Treating Residual Disease in Upper GI Cancers Following FLOT Treatment
The Oncology Brothers and Sam Klempner, MD, offer comprehensive insights on treating residual disease in upper GI cancers following FLOT treatment.
Upper GI Malignancies: Treatment Paradigm for T2 Disease and Beyond
Sam Klempner, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment strategies for esophageal, GE junction, and gastric cancers.
Expert Highlights Applications of Proton Therapy in Radiation Oncology
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Novel Radiotherapy Technology Shows “Great Advantage” in Brain Cancer
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Biomarker Testing in Non–Small Cell Lung Cancer
A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma
The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
The Role of Molecular Profiling in Optimizing Treatment Decisions for RCC
Molecular profiling is a tool that can best determine first-line therapy options for patients with advanced RCC.
Learning How to Manage Immunotherapy or TKI-Related AEs in Advanced RCC
Clinicians are learning how to identify adverse effects relating to either immunotherapy or tyrosine kinase inhibitors for patients with advanced renal cell carcinoma.
A Multifaceted Approach to Optimizing Treatment in RCC
Moshe Ornstein, MD, discusses the heterogeneous population that comprise patients with advanced renal cell carcinoma.
MM Treatment: Clinical Advice on the Care of Patients Receiving Talquetamab
Tiffany Richards, PhD, ANP-BC, and the rest of the panel offer clinical advice on the care of patients with multiple myeloma who are receiving talquetamab.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "A panel of 4 experts on lung cancer")
